🎉 M&A multiples are live!
Check it out!

Ulisse Biomed Valuation Multiples

Discover revenue and EBITDA valuation multiples for Ulisse Biomed and similar public comparables like Genomictree, Biohit, and AnteoTech.

Ulisse Biomed Overview

About Ulisse Biomed

Ulisse Biomed SpA is a healthcare biotech company. It is engaged in developing medical diagnostics, theranostics, and therapeutics solutions. The company has three technology platforms, namely, Sagitta for molecular diagnostics, NanoHybrid for theranostics and diagnostics, and Aptavir for therapeutics.


Founded

2015

HQ

Italy
Employees

10

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

$19.2M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Ulisse Biomed Financials

Ulisse Biomed has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Ulisse Biomed achieved revenue of $0.1M and an EBITDA of -$2.3M.

Ulisse Biomed expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Ulisse Biomed valuation multiples based on analyst estimates

Ulisse Biomed P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $0.2M $0.1M XXX XXX XXX
Gross Profit $0.2M -$0.2M XXX XXX XXX
Gross Margin 112% -154% XXX XXX XXX
EBITDA -$1.1M -$2.3M XXX XXX XXX
EBITDA Margin -678% -1815% XXX XXX XXX
Net Profit -$0.6M -$1.4M XXX XXX XXX
Net Margin -414% -1108% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Ulisse Biomed Stock Performance

As of April 15, 2025, Ulisse Biomed's stock price is EUR 1 (or $1).

Ulisse Biomed has current market cap of EUR 19.0M (or $20.5M), and EV of EUR 17.9M (or $19.2M).

See Ulisse Biomed trading valuation data

Ulisse Biomed Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$19.2M $20.5M XXX XXX XXX XXX n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Ulisse Biomed Valuation Multiples

As of April 15, 2025, Ulisse Biomed has market cap of $20.5M and EV of $19.2M.

Ulisse Biomed's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Ulisse Biomed's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Ulisse Biomed and 10K+ public comps

Ulisse Biomed Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $19.2M XXX XXX XXX
EV/Revenue 151.4x XXX XXX XXX
EV/EBITDA -8.3x XXX XXX XXX
P/E -7.7x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -12.0x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Ulisse Biomed Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Ulisse Biomed Valuation Multiples

Ulisse Biomed's NTM/LTM revenue growth is n/a

Ulisse Biomed's revenue per employee for the last fiscal year averaged $13K, while opex per employee averaged $0.2M for the same period.

Over next 12 months, Ulisse Biomed's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Ulisse Biomed's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Ulisse Biomed and other 10K+ public comps

Ulisse Biomed Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -19% XXX XXX XXX XXX
EBITDA Margin -1815% XXX XXX XXX XXX
EBITDA Growth 117% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee $13K XXX XXX XXX XXX
Opex per Employee $0.2M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue 1915% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Ulisse Biomed Public Comps

See public comps and valuation multiples for Pharma Diagnostics & Analytics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Zomedica XXX XXX XXX XXX XXX XXX
AnteoTech XXX XXX XXX XXX XXX XXX
Proteomics International XXX XXX XXX XXX XXX XXX
Biohit XXX XXX XXX XXX XXX XXX
Genomictree XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Ulisse Biomed M&A and Investment Activity

Ulisse Biomed acquired  XXX companies to date.

Last acquisition by Ulisse Biomed was  XXXXXXXX, XXXXX XXXXX XXXXXX . Ulisse Biomed acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Ulisse Biomed

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Ulisse Biomed

When was Ulisse Biomed founded? Ulisse Biomed was founded in 2015.
Where is Ulisse Biomed headquartered? Ulisse Biomed is headquartered in Italy.
How many employees does Ulisse Biomed have? As of today, Ulisse Biomed has 10 employees.
Is Ulisse Biomed publicy listed? Yes, Ulisse Biomed is a public company listed on MIL.
What is the stock symbol of Ulisse Biomed? Ulisse Biomed trades under UBM ticker.
When did Ulisse Biomed go public? Ulisse Biomed went public in 2021.
Who are competitors of Ulisse Biomed? Similar companies to Ulisse Biomed include e.g. Zomedica, AnteoTech, Proteomics International, Biohit.
What is the current market cap of Ulisse Biomed? Ulisse Biomed's current market cap is $20.5M
What is the current revenue growth of Ulisse Biomed? Ulisse Biomed revenue growth between 2023 and 2024 was -19%.
Is Ulisse Biomed profitable? Yes, Ulisse Biomed is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.